Obesity has been linked to several chronic diseases, including fatty liver disease, heart diabetes mellitus, hypertension, obstructive sleep apnea, and cancer. The purpose of the current study was determine how Orlistat affected renal toxicity, DNA damage, apoptosis that were brought on by obesity in normal obese female rats. There four groups made up a total 20 rats (G1, Control; G2, Orlistat;...

OBJECTIVE Orlistat leads to improved glycemic control in obese type 2 diabetic patients, which is attributed to decreased insulin resistance associated with weight loss. Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are gut hormones that are secreted in response to food intake, and they both stimulate insulin secretion. Orlistat decreases fat absorption and ...

OBJECTIVE Effects of weight loss on vascular function are unknown. We compared, in the face of similar weight loss over 3-6 months, effects of orlistat (120 mg t.i.d., n = 23) and placebo (n = 24) on in vivo endothelial function in a high-risk group of obese (BMI 32.1 +/- 0.4 kg/m(2)) premenopausal nondiabetic women with a history of gestational diabetes. RESEARCH DESIGN AND METHODS Forearm b...

Orlistat is used clinically worldwide as anti-obesity drug. It is a chemically synthesized hydrogenated derivative of lipstatin and is an inhibitor of gastric and pancreatic lipases. It has been found to reduce the absorption of dietary fat in the gastrointestinal tract. Modeling and simulation based on pharmacokinetic/pharmacodynamic analysis is becoming increasingly used in the design of clin...

Objective(s):The current study was aimed to determine the bioactive constituents and biological effects of the Crataegus monogyna ethanolic extracts from bark, leaves and berries on hypercholesterolemia. Materials and Methods: Oleanolic acid, ursolic acid, quercetin and lupeol concentrations were quantified by HPLC. Total phenol content and radical scavenging activity of extracts were also mea...

Objective. Determine the impact of Orlistat-induced weight loss on metabolic profile and cardiovascular function in severely obese patients with type 2 diabetes. Methods. Twenty-nine patients were randomized either to a nonplacebo control group or to a treatment group with Orlistat thrice a day. Metabolic profile, anthropometric parameters, heart rate variability indices, and echocardiographic ...

Orlistat is an orally administered anti-obesity drug that has shown significant antitumor activity in a variety of tumor cells. To identify the proteins involved in its antitumor activity, we employed a proteomic approach to reveal protein expression changes in the human ovarian cancer cell line SKOV3, following Orlistat treatment. Protein express...

Solubility is an important physicochemical factor affecting absorption of drug and there by its therapeutic effect. About 40% of newly discovered drugs are lipophilic and failed to reach market due to their poor water solubility. Solid dispersions proved to have tremendous potential for improving drug solubility. Orlistat is a poor water soluble substance possessing anti-obesity property; in th...

f ackground & Aims: Few controlled studies have adressed the issue of effective medical treatment for onalcoholic fatty liver disease (NAFLD). We herein asessed the effect of orlistat in patients with NAFLD. ethods: We performed a randomized, double-blind, lacebo-controlled study on 52 patients with NAFLD iagnosed by ultrasound (US) and confirmed by liver iopsy (40 patients). The patients were ...

Randomized controlled trials (RCTs) directly comparing weight loss drugs approved in the European Union were reviewed and the results analysed by meta-analysis. Eight RCTs including 885 patients were found comparing weight loss of orlistat and sibutramine, while no study including rimonabant was found. The median study duration was 7 months (range 3-12). Four of the seven studies comparing sibu...